Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2021

Revenue From Contract With Customer [Abstract]

Product and Product-Related Service Revenue from Sale of Instruments and Consumables

Product and Product-related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2021 and 2020 as follows:

	Years Ended December 31,
	2021		2020
Product revenue:
Instrument	$	1,385,665	$	869,035
Consumables		3,786,923		3,030,612
Total product revenue		5,172,588		3,899,647
Product-related services revenue:
Custom RUO assay design		48,350		1,393,316
RUO sample processing		3,685,890		2,597,891
Total product-related services revenue		3,734,240		3,991,207
Total product and product-related services revenue	$	8,906,828	$	7,890,854

Schedule of Collaborative Development Services

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. For the year ended December 31, 2020, collaborative development services revenue was generated through statements of work entered into under a Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”) discussed below.

	Years Ended December 31,
	2021		2020
Collaborative development services	$	—	$	658,010

Schedule of Changes in Contract Liability

Changes in the Company’s contract liabilities were as follows as of the dates indicated:

	Product Revenue			Custom RUO Assay Design		Sample Processing			Total Contract Liability
Balance at January 1, 2021	$	103,580		$	-	$	93,884		$	197,464
Deferral of revenue		286,349			-		587,091			873,440
Recognition of deferred revenue		(261,400	)		-		(650,354	)		(911,754	)
Balance at December 31, 2021	$	128,529		$	—	$	30,621		$	159,150

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2020	$	95,148		$	66,216		$	438,090		$	599,454
Deferral of revenue		500,045			566,733			124,404			1,191,182
Recognition of deferred revenue		(491,613	)		(632,949	)		(186,888	)		(1,311,450	)
Transfer to refund liability		—			—			(281,722	)		(281,722	)
Balance at December 31, 2020	$	103,580		$	—		$	93,884		$	197,464